Nonsteroidal anti-inflammatory drugs, acetaminophen, cyclooxygenase 2, and fever

Clinical Infectious Diseases

Volumn 31, Issue , 2000, Pages S211-S218

  Simmons, D L ^a   Wagner, D ^a   Westover, K ^a  

^a Brigham Young University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIPYRETIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN E2; RESVERATROL; ROFECOXIB;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; CONFERENCE PAPER; DRUG MECHANISM; ENZYME ACTIVITY; FEVER; HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS;

ACETAMINOPHEN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENZYME INDUCTION; FEVER; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MUTATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0034458153     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/317517     Document Type: Article

References (66)

1. The history of aspirin
2. History of aspirin and its mechanism of action
3. The discovery of drugs to treat arthritis: A historical view
4. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
5. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamidophenol)
6. Expression of a mitogen-inducible gene encoding prostaglandin synthase is regulated by mRNA splicing
7. TISI0, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
8. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein
9. Towards a better aspirin
10. Prostaglandin endoperoxide H synthases-1 and -2
11. Prostaglandin synthase-2
12. Cyclooxygenase-2: Molecular biology, pharmacology, and neurobiology
13. Kinetic basis for selective inhibition of cyclooxygenases
14. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4-methysulfonylphenyl)-3-phenyl-2[5H]-furanone], an orally active cyclooxygenase-2-inhibitor
15. 2 synthase
16. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
17. 2 synthase-1
18. Flexibility of the NSA1D binding site in the structure of human cyclooxygenase-2
19. C-terminal Ser/Pro-Thr-Glu-Leu tetrapeptides of prostaglandin endoperoxide H synthases-1 and -2 target the enzymes to the endoplasmic reticulum
20. The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors
21. Fever: Links with an ancient receptor
22. Neurobiological basis of fever
23. 2 in the pathogenesis of fever: An update
24. Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response
25. Cyclooxygenase-2 induced in brain blood vessels during fever evoked by peripheral or central administration of tumor necrosis factor
26. Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1β: A possible site of prostaglandin synthesis responsible for fever
27. Cyclooxygenase 2 mRNA expression in rat brain after peripheral injection of lipopolysaccharide
28. Involvement of cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in the rat brain
29. Brain endothelial cells express cyclooxygenase-2 during lipopolysaccharide induced fever: Light and electron microscopic immunocytochemical studies
30. Induction of cyclooxygenase-2 in the brain by cytokines
31. Intravenous lipopolysaccharide induces cyclooxygenase-2 like immunoreactivity in the rat brain perivascular microglia and meningeal macrophages
32. -/- mice
33. Expression of mRNAs for vasopressin, oxytocin and corticotrophin releasing hormones in the hypothalamus, and of cyclooxygenases-1 and -2 in the cerebral vasculature, of endotoxin-challenged pigs
34. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide
35. Eicosanoid metabolism in cerebromicrovascular endothelium
36. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: Evidence for a vagal mediation of immune-brain communication
37. Blockade of lipopolysaccharide-induced fever by subdiaphragmatic vagotomy in guinea pigs
38. Afferent pathways of pyrogen signaling
39. Blockade of Kupffer cells prevents the febrile and preoptic prostaglandin E2 response to intravenous lipopolysaccharide in guinea pigs
40. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3
41. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach
42. Comparison of the antipyretic actions of indomethacin and L-745,337, a selective cyclooxygenase-2 inhibitor, in endotoxintreated prepubertal pigs
43. Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide
44. Anti-inflammatory effects of etodolac: Comparison with other non-steroidal anti-inflammatory drugs
45. Anti-inflammatory, analgesic, antipyretic, and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance
46. Anti-inflammatory and safety profile of DuP-697, a novel orally effective prostaglandin synthesis inhibitor
47. A selective inhibitor of cyclooxygenase-2 reverses endotoxin-induced pyretic responses in non-human primates
48. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor
49. Rofecoxib [Vioxx, MK-0966; 4-(4-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor: Pharmacological and biochemical profiles
50. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans
51. Paradoxical effects of resveratrol on the two prostaglandin H synthases
52. Resveratrol inhibits cyclooxgyenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells
53. Selectivity of non-steroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
54. Identification of a phorbol ester-repressible v-src-inducible gene
55. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts
56. NSAID-induced apoptosis in Rous sarcoma virus-transformed chicken embryo fibroblasts is dependent on v-src and c-myc and is inhibited by bcl-2
57. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs
58. Induction of cyclooxygenase and nitric oxide synthase in endotoxin-activated J774 macrophages is differentially regulated by indomethacin; enhanced cyclooxygenase-2 protein expression but reduction of inducible nitric oxide synthase
59. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs
60. The effects of a newly developed nonsteroidal anti-inflammatory drug (M-5011) on arachidonic acid metabolism in rheumatoid synovial fibroblasts
61. Inhibition of prostaglandin synthesis up-regulates cyclooxygenase-2 induced by lipopolysaccharide and peroxisomal proliferators
62. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs
63. Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12, 13-myristate-type tumor promoters in immortalized mouse liver cells
64. Regulation of cytosolic COX-2 and prostaglandin E2 production by nitric oxide in activated murine macrophages
65. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxgyenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells